Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
: In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, i...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1417 |
id |
doaj-1aad903aedca480e9502570d6ace2b47 |
---|---|
record_format |
Article |
spelling |
doaj-1aad903aedca480e9502570d6ace2b472020-11-25T01:32:42ZengMDPI AGCancers2072-66942019-09-011110141710.3390/cancers11101417cancers11101417Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual DiseaseLuca Maurillo0Renato Bassan1Nicola Cascavilla2Fabio Ciceri3Hematology Unit, Department of Biomedicine and Prevention, Fondazione Policlinico Tor Vergata, Hospital, 00133 Rome, ItalyHematology Unit, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, 30174 Mestre and Venice, ItalyHematology Unit, Onco-hematology Department, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo (FG), ItalyHematology and Bone Marrow Transplantation Unit, IRCCS S. Raffaele Scientific Institution, 20132 Milan, Italy: In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules.https://www.mdpi.com/2072-6694/11/10/1417Acute myeloid leukemiaminimal residual diseasetailored therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Luca Maurillo Renato Bassan Nicola Cascavilla Fabio Ciceri |
spellingShingle |
Luca Maurillo Renato Bassan Nicola Cascavilla Fabio Ciceri Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease Cancers Acute myeloid leukemia minimal residual disease tailored therapy |
author_facet |
Luca Maurillo Renato Bassan Nicola Cascavilla Fabio Ciceri |
author_sort |
Luca Maurillo |
title |
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease |
title_short |
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease |
title_full |
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease |
title_fullStr |
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease |
title_full_unstemmed |
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease |
title_sort |
quality of response in acute myeloid leukemia: the role of minimal residual disease |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-09-01 |
description |
: In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules. |
topic |
Acute myeloid leukemia minimal residual disease tailored therapy |
url |
https://www.mdpi.com/2072-6694/11/10/1417 |
work_keys_str_mv |
AT lucamaurillo qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease AT renatobassan qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease AT nicolacascavilla qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease AT fabiociceri qualityofresponseinacutemyeloidleukemiatheroleofminimalresidualdisease |
_version_ |
1725080398786985984 |